MACC1 antibody Polyclonal Antibodies Primary antibodies
- Known as:
- MACC1 (anti-) Polyclonal Antibodies Primary antibodies
- Catalog number:
- orb100664
- Product Quantity:
- 100
- Category:
- -
- Supplier:
- Biorb
- Gene target:
- MACC1 antibody Polyclonal Antibodies Primary antibodies
Related genes to: MACC1 antibody Polyclonal Antibodies Primary antibodies
- Gene:
- MACC1 NIH gene
- Name:
- MET transcriptional regulator MACC1
- Previous symbol:
- -
- Synonyms:
- 7A5, SH3BP4L
- Chromosome:
- 7p21.1
- Locus Type:
- gene with protein product
- Date approved:
- 2008-10-14
- Date modifiied:
- 2018-08-15
Related products to: MACC1 antibody Polyclonal Antibodies Primary antibodies
Related articles to: MACC1 antibody Polyclonal Antibodies Primary antibodies
- Colorectal cancer (CRC) remains a major cause of cancer-related morbidity and mortality worldwide. Metastasis regulators and matrix metalloproteinases have been implicated in tumor progression; however, their clinical significance in CRC remains incompletely defined. In this study, the prognostic value of MACC1 and MMP8 expression levels was investigated. A total of 140 patients diagnosed with CRC and 48 healthy controls were included. Serum levels of MACC1 and MMP8 were measured using ELISA. Clinicopathological parameters were recorded, and their associations with biomarker expression were analyzed. Both MACC1 and MMP8 levels demonstrated moderate diagnostic performance with comparable area under the curve values. A strong positive correlation between MACC1 and MMP8 expression was observed. MACC1 expression was significantly associated with metastasis status and tumor stage, whereas MMP8 expression was associated with tumor localization. In survival analyses, established clinicopathological factors, particularly tumor stage and metastasis status, were identified as the primary determinants of overall survival. In multivariate analysis, tumor stage remained the only consistent independent prognostic factor, while MMP8 showed a modest independent association in a separate model. MACC1 did not retain independent prognostic significance. Although MACC1 and MMP8 may have diagnostic and biological relevance in CRC, their prognostic utility appears limited compared to established clinical parameters. Further large-scale prospective studies are needed. - Source: PubMed
Publication date: 2026/05/11
Soydinç Hilal OğuzŞen SenaSerilmez MuratKarabulut Senem - - Source: PubMed
Publication date: 2026/05/14
Hong JiangGu RentongCheng WenLu ChaojingWang Xiaowei - We have previously identified MACC1 and IER2 as functional biomarkers in the context of colorectal cancer. In silico correlation analysis suggested a possible functional connection between the expressions of these biomarkers, given that a significant positive correlation between IER2 and MACC1 RNA was observed. In loss- and gain-of-function experiments, we found that MACC1 positively regulates the expression of IER2. Furthermore, pulldown experiments provided evidence for MACC1-IER2 protein-protein interactions. Functionally, MACC1 enhanced proliferation of HCT116 cells overexpressing IER2 but not of HCT116 cells with knockdown of IER2 expression. Patients with high expressions of both biomarkers lived significantly shorter, whereas those with low concentrations of both markers showed the longest survival. Taken together, these findings show a functional interplay between the colorectal biomarkers MACC1 and IER2, which, in turn, has an impact on the survival of colorectal cancer patients. - Source: PubMed
Publication date: 2026/03/07
Alberto Vilchez Miguel EnriqueKortüm BenediktSchöpe PaulKyjacova LenkaZincke FabianOsterland MarcSmith JaniceWalther WolfgangRau BeateSleeman Jonathan PaulStein Ulrike - Colorectal cancer (CRC) is one of the most common malignancies of the digestive tract globally, characterized by high incidence, difficulty in early diagnosis, and poor prognosis. Traditional screening methods have limitations in sensitivity and specificity, thus necessitating the development of novel, efficient molecular diagnostic approaches. Recent studies have highlighted the crucial role of mitochondrial dysfunction in the initiation and progression of various cancers, suggesting that mitochondria-related genes (MRGs) could serve as promising diagnostic targets for CRC. In this study, we integrated transcriptomic data from 1174 samples across The Cancer Genome Atlas (TCGA) and multiple Gene Expression Omnibus (GEO) public datasets (GSE21510, GSE44076, and GSE9348) and combined it with MRG data from the MitoCarta3.0 database for a systematic analysis of differentially expressed genes (DEGs). Using LASSO regression and SVM-RFE, two machine learning algorithms, we identified eight key MRGs (ABCG2, ANK2, MACC1, PMAIP1, SLC22A5, SLC25A34, ACAT1, and PDK4) and constructed an early diagnostic model for CRC. Receiver operating characteristic (ROC) curve analysis confirmed the diagnostic efficacy of the model. Gene interaction networks were constructed using GeneMANIA, demonstrating the potential synergistic roles of these genes in regulating cellular metabolism, drug efflux, and immune modulation. CIBERSORT immune cell infiltration analysis revealed significant correlations between these genes and various immune cell subtypes, including T cells, macrophages, and dendritic cells. Further integration of single-cell RNA sequencing data (GSE245552) identified the specific expression patterns of the diagnostic model genes across different cell types. Additionally, we conducted an in-depth investigation of the ANK2 gene. Immunohistochemistry (HPA database), qRT-PCR, and western blotting confirmed the significantly low expression of ANK2 in CRC tissues and cell lines. Moreover, TUNEL and angiogenesis assays showed that overexpression of ANK2 significantly promoted cell apoptosis and inhibited angiogenesis, suggesting that ANK2 may function as a key tumor suppressor in CRC. In conclusion, this study proposes and validates a CRC diagnostic model based on differentially expressed mitochondrial genes. We systematically explored the molecular mechanisms and immune microenvironment correlations of the model and confirmed the biological effects through single-cell and molecular biology experiments. Notably, we highlight the potential regulatory role of ANK2 in the progression of CRC. This research provides theoretical support and new directions for early screening, diagnostic biomarker identification, and targeted therapy strategies for CRC. - Source: PubMed
Publication date: 2026/01/31
Ding XiangyuWu HuanhuanYang JiyuanSong HanGuo JianhuiWang XudongZhang XiaopengLi Zhengrui - Epithelial cell-derived microRNAs (miRNAs) are increasingly recognized as contributors to inflammatory bowel disease (IBD) through altered epithelial permeability and inflammatory cytokine production. This prospective study compared epithelial miRNA expression in Crohn's disease (CD) patients and healthy controls, and investigated their immunoregulatory role in experimental IBD models MATERIALS AND METHODS: Terminal ileum samples were collected via ileocolonoscopy from healthy controls and CD patients (remission and active state). Small-RNA sequencing identified unique miRNA profiles, including miR-338-3p and miR-378a-3p, validated by qRT-PCR. In dextran sodium sulfate-induced colitis mice, mimics were administered, and disease severity, gene expression, and immune cell infiltration were assessed by clinical, histological, and molecular assays KEY FINDINGS: miR-338-3p/miR-378a-3p mimics reduced disease activity scores, attenuated colon shortening, and decreased Th17 cell infiltration in colonic tissues. Histological and immunohistochemical analyses confirmed improved tissue integrity and reduced macrophage/T-cell infiltration in the colon. Mechanistically, miR-338-3p targeted MACC1, while miR-378a-3p suppressed IL33, a proinflammatory cytokine linked to CD pathogenesis. - Source: PubMed
Publication date: 2026/01/21
Kim Ki-UkMoon Jung MinLim EunsuDan Kang-BinSeo JeongkukKim KyuwonShin Seung YongMin HyeyoungChoi Chang Hwan